Single-atom inhibition of oncogenic drivers through cysteine coordination

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

Abstract excerpt

Small-molecule inhibitors rely on molecular recognition within suitable binding pockets, leaving many disease-associated proteins difficult to target. Here, we introduce the concept of a single-atom inhibitor in which gold (Au) engages critical cysteine residues of oncogenic drivers to suppress their activity. We used an AI-assisted few-shot learning approach to identify EGFR-targeting peptides for in vivo Au delivery and showed that the lead candidate, 10714, promoted Au accumulation in EGFR-expressing cells and tumors. In vivo, Au exploited its intrinsic affinity for cysteine to inhibit two structurally distinct oncogenic proteins, engaging Cys797 in EGFR T790M and the mutation-derived Cys12 in KRAS G12C adjacent to their respective nucleotide-binding pockets. Structural and computational analyses supported stabilization of inactive nucleotide-bound states, while mutation of these cysteine residues abrogated Au-mediated inhibition. 10714-Au consequently suppressed oncogenic signaling, reduced non-small-cell lung cancer cell viability, and inhibited tumor growth in EGFR- and KRAS-mutant xenograft models and patient-derived organoids. These findings establish proof of principle for single-atom inhibition across structurally distinct oncogenic drivers and suggest that localized atomic coordination could provide an alternative mode of target engagement to conventional pocket-dependent inhibition.